ArticleNPJ vaccines2022
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection.
Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of a 3-dose, 28-day Regimen of PfSPZ Vaccine in Healthy, Adult Participants to Determine Safety, Tolerability and Efficacy Against Heterologous Plasmodium Falciparum Controlled Human Malaria Infection Conducted 3 or 12 Weeks After Immunization
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Pooled it
- Safety, tolerability and immunogenicity of a condensed, multi-dose prime regimen of PfSPZ Vaccine for the prevention of Plasmodium falciparum malaria infection.Malaria journal · 2025Trial
- Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.The Lancet. Infectious diseases · 2024Trial
- Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults.The Journal of clinical investigation · 2024Trial
- Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults.The American journal of tropical medicine and hygiene · 2023Trial
- The exception that proves the rule: Virulence gene expression at the onset of Plasmodium falciparum blood stage infections.PLoS pathogens · 2023Trial
- A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.Science translational medicine · 2022Trial
- Pan-African hybridization of PfSPZ increases antigenic diversity and replicative capacity for malaria vaccine design.JCI insight · 2026Article
- The endemic dilemma: why whole sporozoite malaria vaccine efficacy falls in the field.Trends in parasitology · 2026Review
- Optimal control and cost-effectiveness analysis of PfSPZ vaccination and indoor residual spraying in malaria transmission: a case study in Keerom.Frontiers in public health · 2026Article
- Complete attenuation of Plasmodium falciparum sporozoites by atovaquone-proguanil.EMBO molecular medicine · 2025Article
- Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate.Parasites & vectors · 2025Article
- Intracellular Parasitic Infections Caused byVaccines · 2025Review
- Assessment of Health Status and Creation of a Registry of Potential Research Participants Aged 1.5 to 50 Years on Bioko Island, Equatorial Guinea.The American journal of tropical medicine and hygiene · 2025Article
- Malaria Vaccines: Current Achievements and Path Forward.Vaccines · 2025Review
- Long lived liver-resident memory T cells of biased specificities for abundant sporozoite antigens drive malaria protection by radiation-attenuated sporozoite vaccination.PLoS pathogens · 2025Article
- Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.Immunological reviews · 2025Review
- A model-informed target product profile for population modification gene drives for malaria control.PLOS global public health · 2025Article
- A conserved Plasmodium nuclear protein is critical for late liver stage development.Communications biology · 2024Article
- Whole-sporozoite malaria vaccines: where we are, where we are going.EMBO molecular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 3 institutions in 4 countries.
Funding
Abstract
Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria infection (CHMI) with the same parasites as in the vaccine (homologous) than with genetically distant parasites (heterologous). We sought to identify an immunization regimen that provided similar VE against CHMI with homologous and heterologous Pf for at least 9 weeks in malaria-naïve adults. Such a regimen was identified in part 1 (optimization), an open label study, and confirmed in part 2 (verification), a randomized, double-blind, placebo-controlled study in which VE was assessed by cross-over repeat CHMI with homologous (PfNF54) and heterologous (Pf7G8) PfSPZ at 3 and 9-10 weeks. VE was calculated using Bayesian generalized linear regression. In part 1, vaccination with 9 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.